These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21573251)

  • 21. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
    Hirohata S
    Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
    Fénix-Caballero S; Alegre-del Rey EJ; Castaño-Lara R; Puigventós-Latorre F; Borrero-Rubio JM; López-Vallejo JF
    J Clin Pharm Ther; 2013 Aug; 38(4):286-93. PubMed ID: 23590560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
    Sibilia J
    Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
    Montesu MA; Addis GM; Satta R; Cottoni F
    G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.
    Tracey D; Klareskog L; Sasso EH; Salfeld JG; Tak PP
    Pharmacol Ther; 2008 Feb; 117(2):244-79. PubMed ID: 18155297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
    Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
    Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
    Breedveld FC
    Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidance on the use of adalimumab for juvenile idiopathic arthritis in Japan.
    Yokota S; Imagawa T; Murata T; Tomiita M; Itoh Y; Fujikawa S; Takei S; Mori M
    Mod Rheumatol; 2012 Aug; 22(4):491-7. PubMed ID: 22258637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of biological agents in immune-mediated inflammatory diseases.
    Efthimiou P; Markenson JA
    South Med J; 2005 Feb; 98(2):192-204. PubMed ID: 15759950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.
    Palframan R; Airey M; Moore A; Vugler A; Nesbitt A
    J Immunol Methods; 2009 Aug; 348(1-2):36-41. PubMed ID: 19567252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [What is special about adalimumab?].
    Rodríguez-Blanco I; Toribio J
    Actas Dermosifiliogr; 2008 Feb; 99 Suppl 3():28-32. PubMed ID: 18680688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upside and Downside of Tumor Necrosis Factor Blockers for Treatment of Immune/Inflammatory Diseases.
    Kunnumakkara AB; Thakur KK; Rana V; Bora B; Banik K; Khatoon E; Sailo BL; Shabnam B; Girisa S; Gupta SC; Aggarwal BB
    Crit Rev Immunol; 2019; 39(6):439-479. PubMed ID: 32421957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of etanercept in chronic immune-mediated disease.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Magnani O; Puppo F
    Expert Opin Drug Saf; 2014 May; 13(5):649-61. PubMed ID: 24654562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review on golimumab in the treatment of psoriatic arthritis.
    Urdaneta M; Jethwa H; Sultan R; Abraham S
    Immunotherapy; 2017 Sep; 9(11):871-889. PubMed ID: 28838285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alopecia areata universalis elicited during treatment with adalimumab.
    Pelivani N; Hassan AS; Braathen LR; Hunger RE; Yawalkar N
    Dermatology; 2008; 216(4):320-3. PubMed ID: 18230980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
    Joyau C; Veyrac G; Dixneuf V; Jolliet P
    Clin Exp Rheumatol; 2012; 30(5):700-6. PubMed ID: 22935567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.